Randomized, phase 2 study of CBP501, cisplatin, and nivolumab as ≥3rd line treatment for exocrine pancreatic cancer patients with white blood cell count (WBC) <10,000/mm3.
Veristat was delighted to be part of a multicenter, randomized phase 2 study that assessed the efficacy and safety of CBP501, cisplatin, and nivolumab as ≥3rd line treatment for exocrine pancreatic cancer patients with white blood cell count (WBC) <10,000/mm3 (NCT: 04953962). Results were presented at the ESMO 2023 conference by Dr. Thomas M. Enzler, MD, PhD, Assistant Professor at the Division of Hematology and Oncology, University of Michigan.
downloadPlease fill out this form to access your resource.